Categories AlphaGraphs, Earnings, Health Care

Merck’s stock gains after Q4 results beat estimates

Merck’s (MRK) shares climbed over 3% in morning trade on Friday after the company topped revenue and earnings expectations for the fourth quarter of 2018. Worldwide sales grew 5% to $11 billion from the prior-year quarter. Foreign exchange negatively impacted sales by 3%.

Merck fourth quarter 2018 earnings infographic
Merck Q4 2018 Earnings Infographic

On a GAAP basis, the company reported a net income of $1.8 billion or $0.69 per share during the quarter compared to a net loss of $1.04 billion or $0.39 per share in the year-ago period. Last year’s earnings results included a provisional charge related to US tax legislation. On an adjusted basis, net income grew 3% to $2.7 billion while EPS rose 6% to $1.04.

During the quarter, sales in the Pharmaceutical segment grew 6% helped by strength in oncology and vaccines. Sales were negatively impacted by weakness in virology, loss of market exclusivity for certain products and foreign exchange.

Also see: Merck Q4 2018 Earnings Conference Call Transcript

While higher sales of KEYTRUDA and GARDASIL helped fuel growth in oncology and vaccines, a significant drop in ZEPATIER sales due to tough competition and declining patient volumes hurt virology sales.

In Animal Health, sales increased 6%, driven by inline and newly launched products. The growth reflects higher sales of companion animal and livestock products.

The company expects full-year 2019 revenue to be $43.2 billion to $44.7 billion, including a negative impact from foreign exchange of around 1%. GAAP EPS is expected to be $3.97 to $4.12 while adjusted EPS is expected to be $4.57 to $4.72.

 

Get access to timely and accurate verbatim transcripts that are published within hours of the event.

Most Popular

Netflix (NFLX): Four reasons why this leader will not be easy to overthrow

Netflix (NASDAQ: NFLX) has for long been the undisputed king of the streaming space. The streaming industry is seeing massive growth with several new players entering the field. It also

Fastenal (FAST) sees strong post-COVID prospects: Is the stock a buy?

The demand for services that involve minimal human interaction is on the rise as people continue to practice social distancing. Fastenal Co. (NASDAQ: FAST), a market-leading supplier of vending machines,

HEXO Corp. (HEXO) Earnings: 3Q21 Key Numbers

HEXO Corp. (NYSE: HEXO) reported its third-quarter 2021 earnings results today. Net revenue rose 2% year-over-year to CAD22.6 million. Net loss narrowed to CAD20.7 million from a loss of CAD19.5

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top